Spatial radionuclide deposition data from the 60 km radial area around the Chernobyl nuclear power plant: results from a sampling survey in 1987

The data set “Spatial radionuclide deposition data from the 60 radial km area around the Chernobyl nuclear power plant: results from a sampling survey in 1987” is the latest in a series of data to be published by the Environmental Information Data Centre (EIDC) describing samples collected and analysed following the Chernobyl Nuclear Power Plant accident in 1986. The data result from a survey carried out by the Ukrainian Institute of Agricultural Radiology (UIAR) in April and May 1987 and includes sample site information, dose rate, radionuclide (zirconium-95, niobium-95, ruthenium-106, caesium-134, caesium-137 and cerium-144) deposition, and exchangeable (determined following 1M NH4Ac extraction of soils) caesium-134 and 137. The purpose of this paper is to describe the available data and methodology used for sample collection, sample preparation and analysis. The data will be useful in reconstructing doses to human and wildlife populations, answering the current lack of scientific consensus on the effects of radiation on wildlife in the Chernobyl Exclusion Zone and evaluating future management options for the Chernobyl-impacted areas of Ukraine and Belarus. The data and supporting documentation are freely available from the EIDC under the terms and conditions of the Open Government Licence (Kashparov et al., 2019; https://doi.org/10.5285/a408ac9d-763e-4f4c-ba72-73bc2d1f596d)

Spatial datasets of radionuclide contamination in the Ukrainian Chernobyl Exclusion Zone

The dataset “Spatial datasets of radionuclide contamination in the Ukrainian Chernobyl Exclusion Zone” was developed to enable data collected between May 1986 (immediately after Chernobyl) and 2014 by the Ukrainian Institute of Agricultural Radiology (UIAR) after the Chernobyl accident to be made publicly available. The dataset includes results from comprehensive soil sampling across the Chernobyl Exclusion Zone (CEZ). Analyses include radiocaesium (134Cs and 134Cs) 90Sr, 154Eu and soil property data; plutonium isotope activity concentrations in soil (including distribution in the soil profile); analyses of “hot” (or fuel) particles from the CEZ (data from Poland and across Europe are also included); and results of monitoring in the Ivankov district, a region adjacent to the exclusion zone. The purpose of this paper is to describe the available data and methodology used to obtain them. The data will be valuable to those conducting studies within the CEZ in a number of ways, for instance (i) for helping to perform robust exposure estimates to wildlife, (ii) for predicting comparative activity concentrations of different key radionuclides, (iii) for providing a baseline against which future surveys in the CEZ can be compared, (iv) as a source of information on the behaviour of fuel particles (FPs), (v) for performing retrospective dose assessments and (vi) for assessing natural background dose rates in the CEZ. The CEZ has been proposed as a “radioecological observatory” (i.e. a radioactively contaminated site that will provide a focus for long-term, radioecological collaborative international research). Key to the future success of this concept is open access to data for the CEZ. The data presented here are a first step in this process. The data and supporting documentation are freely available from the Environmental Information Data Centre (EIDC) under the terms and conditions of the Open Government Licence: https://doi.org/10.5285/782ec845-2135-4698-8881-b38823e533bf

АЛГОРИТМИ МОДЕЛЮВАННЯ БІОМЕХАНІКИ АРТИКУЛЯЦІЇ ГУБ ЛЮДИНИ НА ОСНОВІ B-СПЛАЙН-ПОВЕРХОНЬ

It is considered the description of the practical realization of the algorithm of modeling of human articulation of lips in the article.Даётся описание практической реализации моделирования биомеханики артикуляции губ человека.Наведено опис практичної реалізації алгоритму моделювання біомеханіки артикуляції губ людини

CHEMICAL ANALYTICAL APPROACHES OF DETERMINATION OF CONTENT OF CHLOROHYDROCARBONS AND THEIR METABOLITES IN BIOLOGICAL MATRIXES

Improving of methodical approaches to gas chromatography methodologies of determination, of chlorohydrocarbons — vinyl chloride, 1,2-dichloroethane — and their metabolites — chloroethanol, monochloroacetic acid, and. thiodiglycolic acid. — in biological matrixes (blood and. urine) is reviewed. Metrological characteristics were determined. Content of these chemical compounds and. their metabolites in biological matrixes of workers contacting with chlorohydrocarbons was studied

HYGIENIC ASSESSMENT OF JOINT ACTION OF DEFICIENCY OF IODINE AND FLUORIC POLLUTION ON THE CONDITION OF THE THYROID GLAND IN CHILDREN

The content of fluorine in atmospheric air, in soil, and in system of centralized household-drinking water supply of city of Bratsk are studied, data of branch of Federal Budgetary Healthcare Institution «The Center of Hygiene and Epidemiology of Irkutsk Region» in Bratsk and region of Bratsk, data of Bratsk branch of state institution «Irkutsk CGMS - P» are used. The assessment of prevalence of iodine deficiency of children in two ecologically various districts of city of Bratsk is given. Results of obtained data are turned into practical recommendations on prevention of iodine deficiency in conditions of industrial influence of fluorine. In chosen areas examination of children of preschool age is provided. The number of surveyed made 98 persons including 49 girls and 49 boys. Iodine and fluorine excretion with urine, and also content of fluorine in teeth were defined. Iodine in urine was determined with a spectrophotocolorimetry method. The content of fluorine in urine was determined by an electrometric method with the use of fluoride selective electrode complete with pH in meter according to TORMENTS 4.1.773 - 99. Approved, certified methods of definition of fluorine in teeth do not exist in Russian Federation. Fluorine definition in teeth is based on reaction with alizarin complexon and cerium nitrate with formation of the painted connection. Now it is the only reaction used for direct photometric definition of fluorine. We came to conclusion that contents of fluorine in such biosubstrates as urine and teeth in children of the Central district, though doesn>t exceed admissible level, is significantly above the one of children living in settlement Energetic. This results from the fact that atmospheric air in the Central district is more polluted by fluoric connections. It is known that iodine and fluorine are halogens, and the second one possesses more expressed biological activity and can replace the first in the competitive way. Thus, in this research we tried to prove experimentally that urinary iodine indicators directly depend on industrial influence of fluorine

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362